CAR T-Cell Therapy Offers Hope in DLBCL

Article

CAR-T cell therapy is generating excitement for the treatment of diffuse large B-cell lymphoma, according to an update from the JULIET trial.

Findings from the JULIET trial are generating hope and excitement for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma, according to Peter Borchmann, M.D., professor at the University Hospital of Cologne in Germany.

The phase 2 trial is investigating the CAR-T cell therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory DLBCL. Borchmann explained that at the median follow-up of 14 months, the researchers are still seeing a high amount of patients who are responding to treatment. While longer observation is needed, he said that the findings from this study are generating hope that more patients with DLBCL can obtain and remain in remission.

Related Videos
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE